Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways

Journal of Hematology and Oncology

Volumn 1, Issue 1, 2008, Pages

  Lu, Quanyi ^a,b   Lin, Xianghua ^a   Feng, Jean ^a   Zhao, Xiangmin ^a   Gallagher, Ruth ^a   Lee, Marietta Y ^a   Chiao, Jen Wei ^a   Liu, Delong ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHENYLHEXYL ISOTHIOCYANATE; 6-PHENYLHEXYL ISOTHIOCYANATE; HISTONE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 6 RECEPTOR; ISOTHIOCYANIC ACID DERIVATIVE; RAS PROTEIN; VASCULOTROPIN A;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; DNA METHYLATION; DRUG EFFECT; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; ISOTHIOCYANATES; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIPLE MYELOMA; RAS PROTEINS; RECEPTORS, INTERLEUKIN-6; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349138314     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-1-6     Document Type: Article

References (38)

1. Kyle RA, Rajkumar SV: Multiple Myeloma. New Engl J Med 2004, 351:1860-1873.
2. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C: Molecular aspects of multiple myeloma. Ann Oncol 2000, 11:1217-1228.
3. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003, 101:2784-2788. (Pubitemid 36857644)
4. Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R: DNA methylation changes in multiple myeloma. Leukemia 2004, 18:1687-1692. (Pubitemid 39386348)
5. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428. (Pubitemid 34587077)
6. INK4b gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001, 98:244-246.
7. Guillerm G, Depil S, Wolowiec D, Quesnel B: Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica 2003, 88:476-478. (Pubitemid 36547138)
8. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent Hypermethylation of p16 and p15 Genes in Multiple Myeloma. Blood 1997, 89:2500-2506. (Pubitemid 27143298)
9. Mateos MV, García-Sanz R, López-Pérez R, Moro MJ, Ocio E, Hernández J, Megido M, Caballero MD, Fernández-Calvo J, Bárez A, Almeida J, Orfão A, González M, San Miguel F: Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002, 118:1034-1040. (Pubitemid 35025966)
10. Klein B, Zhang X-G, Content J, et al.: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989, 73:517-526. (Pubitemid 19060538)
11. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991, 78:1996-2004.
12. Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A: Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995, 85:487-494.
13. Vacca A, Ribatti D, Presta M, Minischetti M, Lurlaro M, Ria R, Albini A, Bussolino F, Dammacco F: Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood 1999, 93:3064-3073. (Pubitemid 29200799)
14. Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F: A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003, 88:176-185. (Pubitemid 37101495)
15. Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al.: Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000, 79:574-577.
16. Marks PA, Richon VM, Breslow R, Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology 2001, 13:477-483. (Pubitemid 33027900)
17. Luo RX, Dean DC: Chromatin remodeling and transcriptional regulation. Journal of the National Cancer Institute 1999, 91:1288-1294. (Pubitemid 29387570)
18. Mahlknecht U, Hoelzer D: Histone acetylation modifiers in the pathogenesis of malignant disease. Molecular Medicine 2000, 6:623-644.
19. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC: Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101:4055-4062. (Pubitemid 36857886)
20. Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S: Trichostatin A inhbits both ras-induced neurite outgrowth of P12 cells and morphological transformation of NIH3T3 cells. Oncogene 1995, 10:1119-1123.
21. Richon VM, Emiliani S, Verdain E, Webb Y, Breslow R, Rifkind RA, Marks PA: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998, 95:3003-3007. (Pubitemid 28135844)
22. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE: Phase I trial of the histone deacetylase inhibitors, depsipeptid (FR901228) in patients with refractory neoplasms. Clinical Cancer Res 2002, 8(3):718-728. (Pubitemid 34742100)
23. Melnick A, Licht JD: Histone Deacetylases as therapeutic targets in hematologic malignancies. Current Opinion in Hematology 2002, 9:322-332. (Pubitemid 34596877)
24. Catley L, Weisberg E, Tai Y-T, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi N, Schlossman R, Richardson P, Griffin J, Anderson K: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102:2615-2622. (Pubitemid 37193603)
25. Khan SB, Maududi T, Barton K, Ayers J, Alkan S: Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Brit J Haematol 2004, 125(2):156-161. (Pubitemid 38534966)
26. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U: The effects of the histone deacetylase inhibitor valproic acid on cell cycle growth suppression and apoptosis in multiple myeloma. Haematologica 2006, 91:248-251.
27. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research 2000, 60:5165-5170.
28. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39. (Pubitemid 46053039)
29. Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW: Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Intl J Oncol 2006, 28(5):1287-93.
30. Lu L, Liu D, Ma X, Beklomisheva A, Seiter K, Ahmed T, Chiao JW: The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo. Oncol Reports 2006, 16(6):1363-1367.
31. Beklomisheva A, Fang Y, Feng J, Ma X, Dai W, Chiao JW: Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res 2006, 26:1225-1230.
32. Wong IH, Ng MH, Lee JC, Lo KW, Chung YF, Huang DP: Transcriptional silencing of the p16 gene in human myeloma-derived cell lines by hypermethylation. Brit J Haematol 1998, 103(1):168-175. (Pubitemid 28470815)
33. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-spicific PCR: A novel assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826. (Pubitemid 26296693)
34. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi A: A new method for the cytofluorimetric analysis of mitochondrial membrane potentials using the J aggregate forming lipophilic cation 5,5.,6,6.-tetrachloro-1,1.,3,3. tetraethyl benzimidazolyl carbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993, 197:40-45. (Pubitemid 23358874)
35. Fandy TE, Shankar S, Ross RD, Sausville E, Srivastava RK: Interactive effects of HDAC inhibitors and trail on apoptosis are associated with changes in mitochondrial functions and expression of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7:646-657. (Pubitemid 41099418)
36. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, deCastro C, Ravandi F, Helmer R III, Shen L, Nimer SD, Leavitt R, Raza A, Saba H: Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006, 106:1794-1803.
37. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland J: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002, 20:2429-2440. (Pubitemid 34525728)
38. Estey E: Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007, 25:1908-1915. (Pubitemid 46854425)